Iloperidone (Fanapt) vs Perseris

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Perseris

Rights held by Indivior Pharmaceuticals, Inc.; US product discontinued

Approved in Schizophreniasmall molecule
Reliable signal

NCT02109562 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.

Reported efficacy

Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162) (met)

Result source: NCT02109562

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIloperidone (Fanapt)Perseris
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
7 other results
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
  • -1.2 vs -8.2 wk 24.14 · n 408 · Phase 3 · secondary NCT02203838
  • -1.2 vs -4.8 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -9.4 vs -8.2 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -2.4 vs -4.8 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -10 vs -8.2 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -8.3 vs -4.8 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838
CGI-S, change—Trial running · NCT06961968-0.1 vs -0.3+0.2 vs placebowk 24.14 · n 408NCT02203838
7 other results
  • 0 vs -0.3 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -0.9 vs -0.5 120 mg · wk 8 · n 114 · Phase 3 · secondary NCT02109562
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
  • -0.4 vs -0.3 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.1 vs -0.3 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.3 vs -0.3 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -0.2 vs -0.3 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838
PANSS response—Trial running · NCT06961968—Not reported
PSP, change—Trial running · NCT06961968—Not reported
Relapse (% of patients)—Trial running · NCT06961968—Not reported

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Perseris
-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
7 other results
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
  • -1.2 vs -8.2 wk 24.14 · n 408 · Phase 3 · secondary NCT02203838
  • -1.2 vs -4.8 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -9.4 vs -8.2 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -2.4 vs -4.8 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -10 vs -8.2 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -8.3 vs -4.8 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Perseris
-0.1 vs -0.3+0.2 vs placebowk 24.14 · n 408NCT02203838
7 other results
  • 0 vs -0.3 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -0.9 vs -0.5 120 mg · wk 8 · n 114 · Phase 3 · secondary NCT02109562
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
  • -0.4 vs -0.3 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.1 vs -0.3 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.3 vs -0.3 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -0.2 vs -0.3 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Perseris
—Not reported

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Perseris
—Not reported

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Perseris
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Iloperidone (Fanapt): 4 of 4 rows · Perseris: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Perseris
Dropout rate
34.6%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
28.6%120 mgb
NCT02109562 · Phase 3 · combination
show 8 more results
22.4%90 mg
NCT02109562 · Phase 3 · combination
54.5%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
51.6%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
51.5%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
78.3%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
40%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
1.7%120 mgb
NCT02109562 · Phase 3 · combination
show 8 more results
0%90 mg
NCT02109562 · Phase 3 · combination
6.1%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.7%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
11.3%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.4%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
—120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Serious AEs
0.7%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0.9%120 mgb
NCT02109562 · Phase 3 · combination
show 8 more results
0%90 mg
NCT02109562 · Phase 3 · combination
9.1%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.7%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
6.1%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
4.3%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
6.7%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
120 mgb
injection site pain 22.2% (placebo 19.5%)
headache 15.4% (placebo 23.7%)
weight increased 12.8% (placebo 3.4%)
NCT02109562 · Phase 3 · combination
show 8 more results
90 mg
headache 17.4% (placebo 23.7%)
injection site pain 15.7% (placebo 19.5%)
weight increased 13% (placebo 3.4%)
NCT02109562 · Phase 3 · combination
120 mg
injection site pain 21.2% (placebo 7.1%)
injection site induration 9.1% (placebo 0%)
injection site nodule 9.1% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
90 mg
headache 12.9% (placebo 0%)
injection site pain 12.9% (placebo 7.1%)
insomnia 12.9% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
weight increased 14.7% (placebo 3.6%)
injection site pain 12.7% (placebo 7.1%)
injection site nodule 7.1% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
180 mg subcutaneous
upper respiratory tract infection 13%
blood prolactin increased 8.7%
decreased appetite 8.7%
NCT03978832 · Phase 4 · registry result, not featured evidence
120 mg
cough 20%
dyspepsia 20%
weight increased 20%
NCT01677377 · Phase 2 · registry result, not featured evidence
90 mg
weight increased 33.3%
headache 20%
dyspepsia 13.3%
NCT01677377 · Phase 2 · registry result, not featured evidence
60 mg
weight increased 26.7%
headache 20%
rash 20%
NCT01677377 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.
  2. bPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

Time to Relapse NA vs 3.25 placebo months @ 26wk
time to event · months
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Perseris

CGI-S -0.914 vs -0.518 placebo score @ 8wk120 mg
absolute change · score
NCT02109562 · Phase 3 · combination
show 7 more results
-0.1 vs -0.3 placebo score @ 4.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -0.3 placebo score @ 24.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.868 vs -0.518 placebo score @ 8wk90 mg
NCT02109562 · Phase 3 · combination
-0.2 vs -0.3 placebo score @ 4.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.3 vs -0.3 placebo score @ 24.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
0 vs -0.3 placebo score @ 4.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.1 vs -0.3 placebo score @ 24.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Total -10.9 vs -20.2 placebo score @ 52wk120 mg
absolute change · score
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-12.5 vs -20.2 placebo score @ 52wk90 mg
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -20.2 placebo score @ 52wk
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.3 vs -1 placebo score @ 52wk120 mg
absolute change · score
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-0.5 vs -1 placebo score @ 52wk90 mg
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.2 vs -1 placebo score @ 52wk
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Total -0.2 score @ 0wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 2
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.9 score @ 1wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 8
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.7 score @ 2wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 15
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.4 score @ 3wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 22
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 4wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 29
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.5 score @ 7wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 50
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -2.9 score @ 8wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 3 Day 57
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 12wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 4 Day 85
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 1.6 score @ 16wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Day 113-EOS
NCT03978832 · Phase 4 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Perseris's landscape